Dogwood Therapeutics (DWTX) Competitors $4.89 -0.01 (-0.20%) Closing price 09/12/2025 03:46 PM EasternExtended Trading$4.99 +0.10 (+2.04%) As of 09/12/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DWTX vs. SCYX, OKUR, SNTI, XLO, RANI, MURA, RENB, PYRGF, HYPD, and MRSNShould you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include SCYNEXIS (SCYX), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), Xilio Therapeutics (XLO), Rani Therapeutics (RANI), Mural Oncology (MURA), Renovaro (RENB), PyroGenesis Canada (PYRGF), Hyperion DeFi (HYPD), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry. Dogwood Therapeutics vs. Its Competitors SCYNEXIS OnKure Therapeutics Senti Biosciences Xilio Therapeutics Rani Therapeutics Mural Oncology Renovaro PyroGenesis Canada Hyperion DeFi Mersana Therapeutics Dogwood Therapeutics (NASDAQ:DWTX) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends. Does the media favor DWTX or SCYX? In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 1 articles in the media. Dogwood Therapeutics' average media sentiment score of 1.91 beat SCYNEXIS's score of 1.89 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Dogwood Therapeutics Very Positive SCYNEXIS Very Positive Which has stronger valuation and earnings, DWTX or SCYX? Dogwood Therapeutics has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDogwood TherapeuticsN/AN/A-$12.35M-$18.78-0.26SCYNEXIS$3.75M12.52-$21.29M-$0.40-2.80 Is DWTX or SCYX more profitable? Dogwood Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -599.05%. Dogwood Therapeutics' return on equity of 0.00% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets Dogwood TherapeuticsN/A N/A -27.41% SCYNEXIS -599.05%-43.04%-28.21% Which has more volatility and risk, DWTX or SCYX? Dogwood Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Do institutionals and insiders have more ownership in DWTX or SCYX? 9.1% of Dogwood Therapeutics shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 3.9% of Dogwood Therapeutics shares are held by insiders. Comparatively, 4.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts prefer DWTX or SCYX? Dogwood Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 104.50%. Given Dogwood Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dogwood Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryDogwood Therapeutics beats SCYNEXIS on 9 of the 13 factors compared between the two stocks. Get Dogwood Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DWTX vs. The Competition Export to ExcelMetricDogwood TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.35M$3.16B$5.79B$10.19BDividend YieldN/A2.33%5.73%4.60%P/E RatioN/A7.6256.5722.28Price / SalesN/A416.49529.93120.07Price / CashN/A44.4425.8129.91Price / Book-0.659.6112.166.25Net Income-$12.35M-$53.29M$3.29B$270.76M7 Day Performance-0.20%0.13%0.74%3.87%1 Month Performance-0.79%5.55%5.00%5.49%1 Year PerformanceN/A10.44%62.55%25.86% Dogwood Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DWTXDogwood Therapeutics2.1041 of 5 stars$4.89-0.2%$10.00+104.5%N/A$9.35MN/A0.005Positive NewsSCYXSCYNEXIS1.631 of 5 stars$0.92+3.0%N/A-23.3%$37.31M$3.26M-2.2960Positive NewsGap UpOKUROnKure Therapeutics3.5814 of 5 stars$2.63-4.4%$32.33+1,129.4%N/A$37.21MN/A-0.55N/ASNTISenti Biosciences3.3443 of 5 stars$1.32-5.0%$8.50+543.9%-56.0%$36.36M$2.56M-0.154Positive NewsShort Interest ↓XLOXilio Therapeutics2.7648 of 5 stars$0.70-0.6%$3.00+331.2%-10.2%$36.27M$6.34M-0.9270RANIRani Therapeutics3.1803 of 5 stars$0.50-0.4%$7.33+1,366.7%-78.9%$36.09M$1.03M-0.55110Positive NewsShort Interest ↓Gap DownMURAMural Oncology2.5395 of 5 stars$2.07flat$12.00+479.7%-36.8%$35.86MN/A-0.24119Short Interest ↑RENBRenovaro0.8694 of 5 stars$0.19-8.9%N/A-69.7%$35.54MN/A-0.2420High Trading VolumePYRGFPyroGenesis CanadaN/A$0.19-1.5%N/A-67.9%$35.11M$9.14M-3.1290Gap UpHigh Trading VolumeHYPDHyperion DeFi0.3956 of 5 stars$6.48+5.5%$2.00-69.1%-65.1%$34.97M$60K-0.1140News CoverageGap UpMRSNMersana Therapeutics4.0591 of 5 stars$7.04+3.2%$56.60+704.0%-86.5%$34.04M$40.50M-0.48150Positive NewsGap Down Related Companies and Tools Related Companies SCYX Alternatives OKUR Alternatives SNTI Alternatives XLO Alternatives RANI Alternatives MURA Alternatives RENB Alternatives PYRGF Alternatives HYPD Alternatives MRSN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DWTX) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump’s right about Epstein.A crisis that could devastate your wealth, upend the dollar, and accelerate the collapse of America’s economy....Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe Obscure Korean War Act That Created a $5.39 Billion Passive Income StreamAn obscure Korean War law has just been enacted by the U.S. government... Allowing it to take a heavy hand ...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
